Bypass PBM intermediaries for cost-effective, uninterrupted medication access Access branded GLP-1 medications at reduced prices and decide how to share costs with employees Ensure rapid access to GLP-1 medications within 5 days to drive increased persistence anD better health outcomes Higher ROI
Jason Brett, principal US medical head for Novo Nordisk, told CNN in an interview
Because she meets obesity criteria and has an additional metabolic risk factor, she would generally be considered a strong candidate for evaluation
Similarly, if injection site reactions become progressively worse rather than improving, show signs of infection (increasing warmth, spreading redness, pus, or red streaking), or fail to resolve within several days, medical assessment is warranted
Lillys Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Active Psoriatic Arthritis and Obesity or Overweight
The percentages of participants who experienced AE leading to treatment discontinuation as well as of those who experienced gastrointestinal AE with oral semaglutide 50 mg (Tables 2 and 3) were similar to those observed with subcutaneous semaglutide 2.4 mg (in STEP-1 and STEP-2 trials 67% discontinued treatment due to AE, 3444% experienced nausea, 2132% diarrhoea and 2225% vomiting) [11, 29]